COMPASS Pathways to participate in Cowen and Roth investor conferences
02 mars 2022 07h00 HE
|
COMPASS Pathways
LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
24 févr. 2022 07h12 HE
|
COMPASS Pathways
LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and...
COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022
17 févr. 2022 12h21 HE
|
COMPASS Pathways
LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
19 janv. 2022 07h00 HE
|
COMPASS Pathways
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways to participate in H.C. Wainwright investor conference
10 janv. 2022 07h00 HE
|
COMPASS Pathways
LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
04 janv. 2022 07h00 HE
|
COMPASS Pathways
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...
COMPASS Selected for Addition to NASDAQ Biotechnology Index
17 déc. 2021 07h00 HE
|
COMPASS Pathways
London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces changes in Executive Team
16 déc. 2021 07h40 HE
|
COMPASS Pathways
Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
13 déc. 2021 07h00 HE
|
COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...
Michael Falvey joins COMPASS Pathways as Chief Financial Officer
03 déc. 2021 07h00 HE
|
COMPASS Pathways
London, UK - 3 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...